• Careers
  • Contact
AM Pharma
  • Home
  • About Us
    • About AM-Pharma
    • Management Team
    • Supervisory Board
  • Our approach
    • Sepsis-associated acute kidney injury
  • Partnering
  • Investors
  • Media Centre
    • Publications
    • Press Releases
  • Menu Menu

Press releases

AM-Pharma vergroot met extra €47 miljoen de financiering voor klinische fase III-registratiestudie met Nederlands kandidaatmedicijn tegen acuut nierfalen tot €163 miljoen

31st March 2020
Tegen de aandoening bestaat mondiaal nog geen goedgekeurde…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 akiibdh /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png akiibdh2020-03-31 08:00:082020-04-01 11:00:34AM-Pharma vergroot met extra €47 miljoen de financiering voor klinische fase III-registratiestudie met Nederlands kandidaatmedicijn tegen acuut nierfalen tot €163 miljoen

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

1st October 2019
Juliane Bernholz has joined as Chief Operating Officer …
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Janine Versteeg /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Janine Versteeg2019-10-01 10:25:572019-10-01 10:46:42AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

16th July 2019
Financing co-led by new investors LSP and Andera Partners, with…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 akiibdh /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png akiibdh2019-07-16 07:45:452019-07-16 07:45:45AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma haalt €116 miljoen ($133 miljoen) financiering op voor fase III registratie-studie met kandidaat-medicijn tegen acuut nierfalen (AKI)

16th July 2019
Grootste biotech VC financieringsronde ooit in Nederland, geleid…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 akiibdh /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png akiibdh2019-07-16 07:30:242019-07-16 09:00:40AM-Pharma haalt €116 miljoen ($133 miljoen) financiering op voor fase III registratie-studie met kandidaat-medicijn tegen acuut nierfalen (AKI)

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

24th October 2018
View publication
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 akiibdh /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png akiibdh2018-10-24 16:32:372019-07-04 13:08:01Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury

24th October 2018
JAMA paper to be presented at ESICM conference in Paris New…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 akiibdh /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png akiibdh2018-10-24 14:20:582019-06-24 14:30:27JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Page 2 of 6‹1234›»
  • Privacy Policy
© AM-Pharma B.V.
Website by BTTR
linkedin
Scroll to top

We use cookies to help us improve our website by collecting and reporting information on how you use it. For more information about how we use cookies please see our Cookies Policy

AcceptReject


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only